Special Seminar: In Vivo Genome Editing—from Proof-of-Concept to Therapeutic Delivery

Hao Yin, MIT

Monday, May 23, 2016, 3:30–4:30pm

Spanos Auditorium, Cummings Hall

Dr. Hao Yin spearheaded the first demonstration that CRISPR can reverse disease symptoms in living animals, extending its application from in vitro to in vivo. His work, published in 2014 in Nature Biotechnology, has been highlighted in front-page headlines and as cover stories by numerous influential public media and scientific journals worldwide. With expertise in non-viral vectors, he generated clinical suitable delivery methods for CRISPR mediated in vivo gene repair. Published in 2016 in Nature Biotechnology, he developed a lipid-based nanoformulation of Cas9 mRNA for in vivo delivery (named as Nano.Cas9). When Nano.Cas9 was combined with an adenovirus-associated virus vector carrying a guide RNA and a repair template, this treatment induced gene repair with high efficiency and minimal off-target genomic effects in the liver. In collaborations with the laboratories of Professor Phillip Sharp and Professor Tyler Jacks, he is the leading author in another landmark study described in Nature, demonstrating that CRISPR can directly mutate tumor suppressor genes and oncogenes in vivo, creating a new avenue for the rapid development of cancer models and functional genomics.

About the Speaker

Dr. Yin received his BS degree in biotechnology from Nanjing University in Nanjing, China and completed his PhD training at the School of Pharmacy at the University of Colorado Anschutz Medical Campus. In December 2010, he joined the research group of Professor Robert Langer and Professor Daniel Anderson at Massachusetts Institute of Technology (MIT), as a postdoctoral associate. At Langer/Anderson lab, he harnessed novel viral and non-viral delivery vectors and genome engineering technologies for developing gene-based therapy and generating cancer models.

For more information, contact Ellen Wirta at Ellen.K.Wirta@dartmouth.edu.